Acute Kidney Injury, Severe Sepsis, Shock, Septic
Conditions
Brief summary
The primary objective of this study is to compare 28 day mortality rates between septic shock patients with acute renal insufficiency treated via L-Carnitine (as an adjunct therapy) versus a similar group of patients not receiving L-Carnitine adjunct therapy.
Detailed description
The secondary objectives of this study are: A. First secondary objective of this study is to compare 10 day mortality rates of septic shock patients with renal insufficiency treated via L-Carnitine (as an adjunct therapy) for 56 days versus a patients not receiving L-Carnitine adjunct therapy B. To compare study arms in terms of patient safety. C. To compare study arms in terms of further clinical outcomes, with special emphasis on nephrological outcomes. D. To study (and compare between arms) the kinetic curves of free and total serum carnitine. Renal replacement therapy rapidly depletes the body's carnitine levels. Tracking adequate carnitine levels is therefore important for the interpretation of study results. E. To constitute a bio-bank in association with the study for future ancillary studies (e.g. kidney injury marker studies, carnitine-responders versus non-responders, and other exploratory studies.
Interventions
DRUG56 days of weight-adjusted L-Carnitine treatment
Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment. Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml. Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes For the next 46 days, patients will take oral doses of L-Carnitine as follows: \< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization
DRUG10 days of intravenous placebo (isotonic saline)
Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards). Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient * The patient must be insured or beneficiary of a health insurance plan * The patient is at least 18 years old * The patient was admitted to an intensive care unit (participating in the study) for sepsis or septic shock and presented with acute renal failure requiring, at some point, the use of extra-renal purification. * • The patient has sepsis or septic shock according to international criteria SEPSIS 3 (Singer et al, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) ; JAMA. 2016) * The patient has acute renal insufficiency with an KDIGO score of 3 * The patient has started continuous renal replacement therapy (CRRT) or intermittent renal replacement therapy (IRRT) within the previous 72 hours, or will start RRT (CRRT or IRRT) within the next 72 hours.
Exclusion criteria
* • The patient is participating in, or has participated in over the past three months, another interventional study that may interfere with the results or conclusions of this study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, or is an adult under guardianship * The patient is pregnant, parturient or breastfeeding * The patient is susceptible to procreate and does not use methods of effective contraception (contraceptive hormonal ring, surgical contraception, contraceptive implant, contraceptive pill, male or female sheaths, skin patch, intrauterine contraceptive device) * If the patient is unable to sign a consent form: the patient-designated trusted person or family member refuses to sign the consent form * If the patient is unable to sign a consent form: It is impossible to correctly inform the patient-designated trusted person or family member * The patient is able/apt to sign a consent form, but refuses to do so * The patient is able/apt to sign a consent form, but cannot be correctly informed * Septic shock without associated AKI * Patients with a known allergy to L-Carnitine or other component of levocarnil oral solution or for injection * Pre-existing chronic disease requiring dialysis * The patient has stage 4 CKD with baseline DFG (CDK) if known \<30 ml * History of seizures or epilepsy * Chronic bowel disease or history of chronic diarrhoea * Under treatment with sodium valproate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | 28 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| First secondary objective of this study is to compare 10 day mortality rates of septic shock patients with renal insufficiency treated via L-Carnitine (as an adjunct therapy) for 56 days versus a patients not receiving L-Carnitine adjunct therapy. | 10 days | Mortality |
| Adverse Events per patient | 12 months (throughout study) | — |
| Survival | 12 months (throughout study) | — |
| The number of days alive and not on renal replacement therapy | 12 months | — |
| The number of days alive and free of renal failure | 12 months | — |
| The number of days alive and not on mechanical ventilation | 12 months | — |
| The number of days alive and not in Intensive Care Unit (ICU) | 12 months | — |
| The number of days alive and not in hospital | 12 months | — |
| The number of days alive and free of organ failure | 12 months | — |
| A vector of repeated measures of daily SOFA (Sequential Organ Failure Assessment score) scores available during the ICU stay | at ICU discharge (expected max of 28 days) | Available daily scores will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope). |
| A vector of repeated measures of AKIN (Acute Kidney Injury Network score) score available during the ICU stay | at ICU discharge (expected max of 28 days) | Available daily scores will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope). |
| A vector of repeated measures of serum creatinine | at ICU discharge (expected max of 28 days) | Available measures will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope). |
| A vector of repeated measures of lactate levels available during the ICU stay | at ICU discharge (expected max of 28 days) | Available measures will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope). |
| Glomerular filtration rate (EpiCKD) | month 1 | (if the patient is on dialysis, the glomerular filtration rate is set at 0) |
| Serum free carnitine level | baseline | — |
| Serum total carnitine level | baseline | — |
| The number of days alive and free of (not requiring) catecholamines | 12 months | — |
Countries
France
Outcome results
None listed